dc.contributor.author |
Beran, David |
|
dc.contributor.author |
Abidha, Carol |
|
dc.contributor.author |
Adler, Amanda |
|
dc.contributor.author |
de Beaufort, Carine |
|
dc.contributor.author |
Lepeska, Molly |
|
dc.contributor.author |
Levitt, Naomi |
|
dc.contributor.author |
Pfiester, Elizabeth |
|
dc.contributor.author |
Zafra Tanaka, Jessica Hanae |
|
dc.contributor.author |
Gale, Edwin Am |
|
dc.date.accessioned |
2023-02-20T13:28:11Z |
|
dc.date.available |
2023-02-20T13:28:11Z |
|
dc.date.issued |
2023 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12866/13159 |
|
dc.description.abstract |
The US Food and Drug Administration's (FDA) approval of teplizumab to delay the onset of type 1 diabetes could be seen as symbolic, because it came a century after the first use of insulin. Teplizumab, an anti-CD3 monoclonal antibody, is now approved in the USA for people at high risk of type 1 diabetes. This approval is a highly welcome development for this population and all those involved in the care and wellbeing of people with type 1 diabetes. However, in our opinion, the approval of teplizumab should be interpreted with caution. A global health perspective must consider evidence, cost, patient preferences, and equity... |
en_US |
dc.language.iso |
eng |
|
dc.publisher |
Elsevier |
|
dc.relation.ispartofseries |
Lancet. Diabetes and Endocrinology |
|
dc.rights |
info:eu-repo/semantics/restrictedAccess |
|
dc.rights.uri |
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es |
|
dc.subject |
Teplizumab |
en_US |
dc.subject |
type 1 diabetes |
en_US |
dc.subject |
USA |
en_US |
dc.subject.mesh |
Diabetes Mellitus, Type 1 |
|
dc.subject.mesh |
United States |
|
dc.title |
Teplizumab approval for type 1 diabetes in the USA. |
en_US |
dc.type |
info:eu-repo/semantics/article |
|
dc.identifier.doi |
https://doi.org/10.1016/S2213-8587(22)00384-9 |
|
dc.subject.ocde |
https://purl.org/pe-repo/ocde/ford#3.02.18 |
|
dc.relation.issn |
2213-8595 |
|